Prohepcidin, B-type natriuretic peptide, and iron status in a cohort of elderly women from the Rhine-Ruhr area by Henry, J. et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Brief Communication 
 Acta Haematol 2010;124:129–133 
 DOI: 10.1159/000318817 
 Prohepcidin, B-Type Natriuretic Peptide, 
and Iron Status in a Cohort of Elderly 
Women from the Rhine-Ruhr Area 
 Jana Henry  a    Swaantje Casjens  a    Tamara Schikowski  d    Axel Stachon  b    
Alfried Germing  c    Ulrich Ranft  d    Martin Lehnert  a    Volker Harth  a    
Ursula Krämer  d    Thomas Brüning  a    Beate Pesch  a   
 a   Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA),
 b   Institute of Clinical Chemistry, Transfusion, and Laboratory Medicine, and  c   Medical Clinic II, Cardiology and 
Angiology, BG-University Hospital Bergmannsheil, Ruhr University Bochum,  Bochum , and  d   Environmental Health 
Research Institute (IUF),  Düsseldorf , Germany 
Air pollution on Lung function, Inflammation and Ag-
ing) cohort investigation. Therefore, prohepcidin, the 
84-amino acid precursor of hepcidin, was determined by 
a commercial assay to be a potential surrogate marker for 
hepcidin which can be used in routine laboratory exami-
nation. Some studies have investigated the association 
between prohepcidin and parameters of iron status, with 
conflicting results  [7–17] . According to our knowledge, 
this parameter has not yet been determined in a popula-
tion of elderly women.
 Among different diseases associated with iron defi-
ciency (ID) and anemia, anemia is common in patients 
with heart failure  [18–20] . B-type natriuretic peptide 
(BNP) is a reliable marker of left ventricular dysfunction. 
Elevated BNP concentrations are associated with a poor 
outcome in patients with heart failure and coronary ar-
tery disease. Studies have shown that BNP concentrations 
in cardiac patients  [21–23] and in the general population 
are inversely and independently related to Hb concentra-
tions  [24] . This suggests that elevated BNP concentra-
 The elderly constitute a fast growing segment of popu-
lations worldwide. Both anemia and iron overload have 
emerged as risk factors that are associated with a variety 
of adverse outcomes in older adults  [1–5] . Standard labo-
ratory parameters like serum ferritin (SF), transferrin, 
transferrin saturation (Tsat), serum iron (SI), Hb, MCV, 
and HCT are commonly used for the assessment of iron 
status, but rapid progress has been made in understand-
ing the regulation of iron metabolism by the hepatic pep-
tide hormone hepcidin  [6] . Hepcidin is synthesized in
response to elevated plasma iron stores, thus ensuring
homeostasis. Hepcidin synthesis is also increased by in-
fection and inflammation. Increased hepcidin concen-
trations are of major importance in anemia of inflamma-
tion and iron-resistant iron deficiency anemia (IDA). On 
the other hand hepcidin is decreased in diseases that are 
attended by iron overload like most hereditary hemo-
chromatoses or iron-loading anemias. A commercial as-
say for the measurement of serum hepcidin was not avail-
able at the time of the SALIA (Study on the influence of 
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tions in anemic patients with chronic heart diseases are 
partially caused by anemia. If prohepcidin is a reliable 
biomarker for iron status, especially for anemia, an asso-
ciation of BNP with prohepcidin concentrations should 
be expected.
 The SALIA cohort was part of a comprehensive envi-
ronmental health survey on the effect of air pollution on 
women’s health in the Rhine-Ruhr area  [25–29] . Here we 
report on parameters of iron status in 319 women aged 
69–79 years measured at follow-up in 2007/2008, includ-
ing prohepcidin, and their association with BNP. All par-
ticipants gave their written informed consent. The study 
was approved by the ethics commission of Ruhr Univer-
sity Bochum and was conducted in accordance with the 
definitions of the declaration of Helsinki.
 WBC, RBC, MCV, Hb, HCT, SF, SI, transferrin, BNP, 
C-reactive protein, alanine aminotransferase, aspartate 
aminotransferase, cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol, and tri-
glycerides were analyzed with standard laboratory meth-
ods. Serum prohepcidin concentrations were analyzed 
in 1 batch using an ELISA kit (EIA-4644; DRG Instru-
ments, Ltd., Marburg, Germany). The normal range of 
prohepcidin was given by the manufacturer (58.9–158.1 
ng/ml).
 Anemia was defined as Hb  ! 12 g/dl and HCT  ! 36% 
for women according to the WHO. ID was defined as an 
abnormal value from 2 or 3 laboratory tests of iron status 
(SF, Tsat, and MCV)  [30] , and IDA was defined as ID plus 
Hb  ! 12 g/dl. The definition of high iron stores is incon-
sistent throughout the literature, but it is well accepted 
that SF concentrations  1 300   g/l for men and  1 200   g/l 
for women are suitable cutoff criteria for high iron stores 
 [30, 31] . We used both thresholds for our calculations be-
cause several studies suggest 200   g/l as the cutoff for SF 
in elderly women  [32–34] .
 Figure 1 shows the distribution of prohepcidin in this 
cohort of elderly women [median 68.2 ng/ml, interquar-
tile range (IQR) 57.0–80.0]. The concentrations are, on 
average, lower than the measurements in 40 younger 
women provided by the manufacturer (median 85.6 ng/
ml, IQR 72.9–91.5, p  ! 0.0001). This is in line with a few 
findings from smaller studies which suggest that prohep-
cidin concentrations are age- and gender-dependent  [12, 
13, 35–37] . 
 The median concentrations of the standard measure-
ments of iron status and other conditions fell within the 
reference range, except for cholesterol (data not shown). 
The prevalence rates of impaired iron status were low in 
this group of nonhospitalized women ( table 1 ). On the 
basis of low Hb values ( ! 12 g/dl according to the WHO), 
10 (3.1%) women were classified as anemic with no fur-
ther specification and 5 women (1.6%) were classified as 
having ID. IDA was observed in 2 women. Although lim-
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 Fig. 1. Distribution of prohepcidin con-
centrations in 319 elderly women from the 
SALIA cohort and in a group of 40 women 
(data provided by DRG Instruments). 
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ited by a small number of cases, we found some evidence 
that ID and IDA were more common in the subgroup of 
women of a higher age ( 1 73 years). The low prevalence of 
ID and IDA in this study is in line with other investiga-
tions in healthy white women  [30, 38] .
 We observed high iron stores more frequently in wom-
en below 73 years of age, independently of the 2 thresh-
olds. Using the more commonly applied gender-specific 
cutoff for SF ( 1 200   g/l), 11.6% of the SALIA women 
showed elevated iron stores which corresponds with the 
observations of 12.2% in the Framingham Heart Study 
cohort  [30] and of 16.6% in healthy elderly Parisian wom-
en  [39] . Using the higher cutoff ( 1 300   g/l) the preva-
lence was 3.4% in the SALIA cohort, 6% in the Framing-
ham cohort, and 3.7% in elderly Danish women  [38] .
 Table  2 describes selected associations between iron 
status measures and other laboratory variables using 
Spearman’s correlation coefficients (r s ). No associations 
were found between prohepcidin and parameters of iron 
status and BNP, while BNP correlated inversely with 
standard parameters of iron status (Hb, HCT, SF, and SI). 
There was no correlation of BNP with risk factors for cor-
onary artery disease like elevated triglycerides, choles-
terol, and low-density lipoprotein cholesterol or lowered 
high-density lipoprotein cholesterol concentrations.
 Data on the role of prohepcidin with regard to iron 
status are inconsistent. Some studies found an associa-
tion between prohepcidin and parameters of iron status 
 [7–11] , while other studies did not  [12–17] . The majority 
of these studies were limited by small numbers. Accord-
ing to our knowledge, SALIA is one of the largest study 
populations with prohepcidin analysis. We observed no 
association between prohepcidin and any marker of iron 
Table 1.  Iron status in elderly women from the SALIA cohort
Cutoff All
women
(n = 319)
Women 
aged
<73 years
(n = 179)
Women 
aged
≥73 years
(n = 140)
Laboratory variable
SF, g/l <15 8 (2.5) 5 (2.8) 3 (2.1)
SI, g/dl <60 30 (9.4) 13 (7.3) 17 (12.1)
Transferrin, mg/dl <200 15 (4.7) 7 (3.9) 8 (5.7)
Tsat, % <16 30 (9.4) 15 (8.4) 15 (10.7)
Hb, g/dl <12 10 (3.1) 2 (1.1) 8 (5.7)
HCT, % <36 23 (7.2) 10 (5.6) 13 (9.3)
MCV, fl <80 2 (0.6) 1 (0.6) 1 (0.7)
Iron status
ID 5 (1.6) 2 (1.1) 3 (2.1)
IDA 2 (0.6) 0 (0.0) 2 (1.4)
High iron stores
SF, g/l >200 37 (11.6) 23 (12.8) 14 (10.0)
SF, g/l >300 11 (3.4) 9 (5.0) 2 (1.4)
F igures in parentheses are percentages.
Table 2.  Spearman’s correlation coefficients with 95% confidence limits between iron status measures and other laboratory variables 
in elderly women from the SALIA cohort
Marker Prohepcidin SF SI Transferrin Tsat Hb HCT MCV
Prohepcidin 1.00
SF 0.06
(–0.05, 0.17)
1.00
SI –0.02
(–0.13, 0.09)
0.24*
(0.13, 0.34)
1.00
Transferrin 0.07
(–0.04, 0.18)
–0.33*
(–0.43, –0.23)
0.08
(–0.03, 0.19)
1.00
Tsat –0.07
(–0.17, 0.05)
0.36*
(0.26, 0.45)
0.85*
(0.81, 0.88)
–0.40*
(–0.49, –0.30)
1.00
Hb 0.10
(–0.01, 0.21)
0.13
(0.02, 0.24)
0.40*
(0.30, 0.49)
0.18*
(0.08, 0.29)
0.25*
(0.15, 0.35)
1.00
HCT 0.09
(–0.02, 0.20)
0.09
(–0.02, 0.20)
0.35*
(0.25, 0.44)
0.20*
(0.09, 0.30)
0.20*
(0.09, 0.30)
0.97*
(0.96, 0.98)
1.00
MCV –0.08
(–0.19, 0.03)
0.31*
(0.21, 0.40)
0.36*
(0.26, 0.45)
–0.05
(–0.16, 0.06)
0.35*
(0.24, 0.44)
0.07
(–0.04, 0.18)
0.03
(–0.08, 0.14)
1.00
BNP –0.05
(–0.16, 0.06)
–0.13
(–0.24, –0.02)
–0.11
(–0.22, –0.0005)
0.01
(–0.10, 0.12)
–0.10
(–0.21, 0.01)
–0.19*
(–0.30, –0.08)
–0.17
(–0.27, –0.06)
–0.08
(–0.19, 0.03)
* p < 0.001.
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status in nonhospitalized elderly women. The assumed 
association of prohepcidin as a reliable marker for iron 
status with BNP could not be confirmed in our study. 
This supports the conclusion that prohepcidin is likely 
not a suitable surrogate marker of the active form of the 
peptide hepcidin in healthy populations. Recent studies 
report that hepcidin concentrations in serum are much 
lower than prohepcidin concentrations are  [40, 41] ; thus, 
fluctuations in hepcidin levels might be associated with 
minor changes in prohepcidin concentrations. It is im-
portant to note that the ELISA assay might not be suffi-
ciently specific for prohepcidin. It has been suggested 
that the antibody also recognizes the proregion of hepci-
din  [42] . Currently, a commercial immunoassay for hu-
man serum hepcidin is being developed  [43] and will be 
investigated using stored SALIA samples.
 In conclusion, a low prevalence of ID and anemia was 
observed in the SALIA cohort of healthy elderly women. 
Prohepcidin was not associated with the standard pa-
rameters of iron metabolism and BNP. We confirmed an 
expected negative correlation between iron status mea-
sures and BNP. 
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